NextCell Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is September - August.

Millions SEK. Fiscal year is Sep - Aug.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	2020 - 2016
Net Income	-35.14	-41.96	-39.81	-34.55	-24.56	Upgrade
Depreciation & Amortization	2.52	0.97	0.45	0.46	0.44	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	0.14	-	Upgrade
Other Operating Activities	-	-0	-	-	-	Upgrade
Change in Accounts Receivable	-1.79	3.17	-7.59	-1.56	-3.24	Upgrade
Change in Inventory	-	0.25	-0.02	-0.77	-	Upgrade
Change in Accounts Payable	-3.47	5.26	-1.03	0.64	0.98	Upgrade
Change in Other Net Operating Assets	-0.98	-5.47	4.18	2.33	0.8	Upgrade
Operating Cash Flow	-38.86	-37.78	-43.83	-33.31	-25.58	Upgrade
Capital Expenditures	-4.18	-0.08	-4.1	-7.59	-0.73	Upgrade
Investment in Securities	-0.06	-0	-0	-1.76	-5.11	Upgrade
Other Investing Activities	-0	-	-	-	-	Upgrade
Investing Cash Flow	-4.24	-0.08	-4.1	-9.35	-5.84	Upgrade
Long-Term Debt Issued	1.1	0.8	0.84	0.61	0.2	Upgrade
Net Debt Issued (Repaid)	1.1	0.8	0.84	0.61	0.2	Upgrade
Issuance of Common Stock	36.56	40.09	-	-	164.72	Upgrade
Other Financing Activities	-2.63	-6.25	-	-	-16.29	Upgrade
Financing Cash Flow	35.03	34.63	0.84	0.61	148.63	Upgrade
Miscellaneous Cash Flow Adjustments	0	-	-	-	-	Upgrade
Net Cash Flow	-8.07	-3.23	-47.09	-42.05	117.21	Upgrade
Free Cash Flow	-43.05	-37.86	-47.92	-40.9	-26.3	Upgrade
Free Cash Flow Margin	-389.04%	-335.70%	-343.41%	-656.63%	-590.41%	Upgrade
Free Cash Flow Per Share	-0.56	-0.93	-1.39	-1.19	-0.86	Upgrade
Cash Interest Paid	0	0	0	0.01	0.01	Upgrade
Levered Free Cash Flow	-30.33	-22.93	-33.74	-28.38	-17.26	Upgrade
Unlevered Free Cash Flow	-30.33	-22.93	-33.74	-28.37	-17.26	Upgrade
Change in Working Capital	-6.24	3.21	-4.46	0.65	-1.46	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.